ArticleEMBO molecular medicine2022
KRAS signaling in malignant pleural mesothelioma.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Tumor mutational burden as a determinant of metastatic dissemination patterns.Molecular oncology · 2026Article
- Bioinformatics reveals TNFAIP6 as a candidate gene and suggests its potential crosstalk in the treatment of hemodialysis in chronic kidney disease.Renal failure · 2025Article
- Pyrimidine addiction: an Achilles' heel of NF2-altered mesothelioma.EMBO molecular medicine · 2025Article
- De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.EMBO molecular medicine · 2025Article
- Exploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells.Medical oncology (Northwood, London, England) · 2025Article
- Mesothelioma cell heterogeneity identified by single cell RNA sequencing.Scientific reports · 2025Article
- NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.NPJ precision oncology · 2024Review
- Article
- Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.Cancers · 2023Review
- KRAS Mutations Are Associated with Shortened Survival in Patients with Epithelioid Malignant Pleural Mesothelioma.Cancers · 2023Article
- MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.Cell death discovery · 2023Article
- Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.Frontiers in immunology · 2023Article
- Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.Frontiers in immunology · 2023Article
- Shape-specific characterization of colorectal adenoma growth and transition to cancer with stochastic cell-based models.PLoS computational biology · 2023Article
- Review
- An In Vivo Inflammatory Loop Potentiates KRAS Blockade.Biomedicines · 2022Article
- KRAS signaling in malignant pleural mesothelioma.EMBO molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 8 institutions in 5 countries.
Antonia Marazioti *Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Anthi C Krontira *Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.
Sabine J Behrend *Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.ORCID 0000-0001-7549-1332
Georgia A Giotopoulou *Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.ORCID 0000-0001-5621-6802
Giannoula Ntaliarda *Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.ORCID 0000-0002-2299-6027
Christophe BlanquartUniversité de Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Hasan BayramDepartment of Pulmonary Medicine, Koc University School of Medicine, Istanbul, Turkey.ORCID 0000-0002-5236-766X
Marianthi IliopoulouLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.
Malamati VrekaComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Lilith TrasslComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Mario A A PepeComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Caroline M HacklComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Laura V KlotzComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.
Stefanie A I WeissComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.ORCID 0000-0002-4059-7417
Ina KochGerman Center for Lung Research (DZL), Gießen, Germany.
Michael LindnerGerman Center for Lung Research (DZL), Gießen, Germany.
Rudolph A HatzGerman Center for Lung Research (DZL), Gießen, Germany.
Juergen BehrGerman Center for Lung Research (DZL), Gießen, Germany.
Darcy E WagnerComprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.ORCID 0000-0003-3794-1309
Helen PapadakiDepartment of Anatomy, Faculty of Medicine, University of Patras, Rio, Greece.
Sophia G AntimisiarisLaboratory for Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, Rio, Greece.
Didier JeanCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Functional Genomics of Solid Tumors, Paris, France.ORCID 0000-0001-5823-7404
Sophie DeshayesUniversité de Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Marc GrégoireUniversité de Nantes, CNRS, INSERM, CRCINA, Nantes, France.
Özgecan KayalarKoc University Research Center for Translational Medicine (KUTTAM), Koc University School of Medicine, Istanbul, Turkey.ORCID 0000-0001-9107-2381
Deniz MortazaviKoc University Research Center for Translational Medicine (KUTTAM), Koc University School of Medicine, Istanbul, Turkey.
Şükrü DilegeDepartment of Thoracic Surgery, Koc University School of Medicine, Istanbul, Turkey.
Serhan TanjuDepartment of Thoracic Surgery, Koc University School of Medicine, Istanbul, Turkey.ORCID 0000-0002-2363-233X
Suat ErusDepartment of Thoracic Surgery, Koc University School of Medicine, Istanbul, Turkey.ORCID 0000-0002-6162-3266
Ömer YavuzDepartment of Thoracic Surgery, Koc University School of Medicine, Istanbul, Turkey.ORCID 0000-0002-7366-2772
Pınar BulutayDepartment of Pathology, Koc University School of Medicine, Istanbul, Turkey.
Pınar FıratDepartment of Pathology, Koc University School of Medicine, Istanbul, Turkey.
Ioannis PsallidasLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.
Magda SpellaLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.ORCID 0000-0003-2505-7778
Ioanna GiopanouLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.
Ioannis LilisLaboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, Rio, Greece.ORCID 0000-0002-0483-4120
Anne-Sophie Lamort *Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.ORCID 0000-0001-5495-9995
Georgios T Stathopoulos *Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), Helmholtz Center Munich-German Research Center for Environmental Health (HMGU) and Ludwig-Maximilian-University (LMU) Munich, Munich, Germany.ORCID 0000-0002-9215-6461
University of Patras · GRKoç University · TRHelmholtz Zentrum München · DEAsklepios Fachkliniken München-Gauting · DECentre National de la Recherche Scientifique · FRGerman Center for Lung Research · DEInserm · FRLund University · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos-exposed individuals and rapidly leads to death. MPM harbors loss-of-function mutations in BAP1, NF2, CDKN2A, and TP53, but isolated deletion of these genes alone in mice does not cause MPM and mouse models of the disease are sparse. Here, we show that a proportion of human MPM harbor point mutations, copy number alterations, and overexpression of KRAS with or without TP53 changes. These are likely pathogenic, since ectopic expression of mutant KRAS
Indexed as
Lung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsHumansMiceSignal TransductionTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Tumor Suppressor ProteinsUbiquitin ThiolesteraseasbestosBAP1KRASNF2TP53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.